secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001104659-22-114196
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q3 GAAP net income $50M; LINZESS Rx demand up 10% YoY, surpasses 1M quarterly scripts
--------------------------------------------------------------------------------

- GAAP net income of $50M ($0.28 diluted EPS); adjusted EBITDA $69M; total revenue $108.6M vs. $103.7M YoY.
- LINZESS prescription demand grew 10% YoY in Q3; exceeded 1M total prescriptions in a quarter for first time.
- Plan to submit sNDA to FDA for functional constipation in pediatric patients (ages 6-17) by end of 2022.
- Reaffirms FY2022 guidance: total revenue $420-$430M, adjusted EBITDA >$250M, LINZESS net sales low single digit % growth.
- Ended Q3 with $574M cash; no debt on balance sheet; strong liquidity position.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465922114196/0001104659-22-114196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465922114196/tm2229423d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-114196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer